These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 19372898)

  • 1. Adipocyte dysfunction in response to antiretroviral therapy: clinical, tissue and in-vitro studies.
    Caron M; Vigouroux C; Bastard JP; Capeau J
    Curr Opin HIV AIDS; 2007 Jul; 2(4):268-73. PubMed ID: 19372898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo.
    Lagathu C; Kim M; Maachi M; Vigouroux C; Cervera P; Capeau J; Caron M; Bastard JP
    Biochimie; 2005 Jan; 87(1):65-71. PubMed ID: 15733739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of antiretroviral-induced mitochondrial dysfunction in adipocytes and adipose tissue: in-vitro, animal and human adipose tissue studies.
    Villarroya F; Domingo P; Giralt M
    Curr Opin HIV AIDS; 2007 Jul; 2(4):261-7. PubMed ID: 19372897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lipodystrophies related to antiretroviral treatment of HIV infection].
    Capeau J; Caron M; Vigouroux C; Cervera P; Kim M; Maachi M; Lagathu C; Bastard JP
    Med Sci (Paris); 2006 May; 22(5):531-6. PubMed ID: 16687123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.
    Nolan D; John M; Mallal S
    Antivir Ther; 2001 Sep; 6(3):145-60. PubMed ID: 11808750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.
    Gougeon ML; Pénicaud L; Fromenty B; Leclercq P; Viard JP; Capeau J
    Antivir Ther; 2004 Apr; 9(2):161-77. PubMed ID: 15134178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adipose tissue inflammation and altered adipokine and cytokine production in antiretroviral therapy-associated lipodystrophy.
    Hammond E; Nolan D
    Curr Opin HIV AIDS; 2007 Jul; 2(4):274-81. PubMed ID: 19372899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals.
    Gerschenson M; Shiramizu B; LiButti DE; Shikuma CM
    Antivir Ther; 2005; 10 Suppl 2():M83-9. PubMed ID: 16152709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study.
    Kim MJ; Leclercq P; Lanoy E; Cervera P; Antuna-Puente B; Maachi M; Dorofeev E; Slama L; Valantin MA; Costagliola D; Lombes A; Bastard JP; Capeau J
    Antivir Ther; 2007; 12(8):1273-83. PubMed ID: 18240867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapies.
    McComsey GA; Walker UA
    Mitochondrion; 2004 Jul; 4(2-3):111-8. PubMed ID: 16120376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In combination, nucleoside reverse transcriptase inhibitors have significant effects on 3T3-L1 adipocyte lipid accumulation and survival.
    Kosmiski LA; Miller HL; Klemm DJ
    Antivir Ther; 2006; 11(2):187-95. PubMed ID: 16640100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-associated lipodystrophy: from fat injury to premature aging.
    Caron-Debarle M; Lagathu C; Boccara F; Vigouroux C; Capeau J
    Trends Mol Med; 2010 May; 16(5):218-29. PubMed ID: 20400373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis and treatment of lipodystrophy: what clinicians need to know.
    Sattler FR
    Top HIV Med; 2008; 16(4):127-33. PubMed ID: 18838747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy.
    Mallon PW
    AIDS Rev; 2007; 9(1):3-15. PubMed ID: 17474309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment strategies for HIV lipodystrophy.
    Carr A
    Curr Opin HIV AIDS; 2007 Jul; 2(4):332-8. PubMed ID: 19372908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depot-specific adipocyte cell lines reveal differential drug-induced responses of white adipocytes--relevance for partial lipodystrophy.
    Kovsan J; Osnis A; Maissel A; Mazor L; Tarnovscki T; Hollander L; Ovadia S; Meier B; Klein J; Bashan N; Rudich A
    Am J Physiol Endocrinol Metab; 2009 Feb; 296(2):E315-22. PubMed ID: 19033543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metabolic side effects of antiretroviral therapy].
    van der Valk M; Reiss P
    Ned Tijdschr Geneeskd; 2008 May; 152(22):1260-4. PubMed ID: 18590059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From lipodystrophy and insulin resistance to metabolic syndrome: HIV infection, treatment and aging.
    Capeau J
    Curr Opin HIV AIDS; 2007 Jul; 2(4):247-52. PubMed ID: 19372895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical management of HIV-associated lipodystrophy.
    Pirmohamed M
    Curr Opin Lipidol; 2009 Aug; 20(4):309-14. PubMed ID: 19494771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
    Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.